Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Still a Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $23.20, but opened at $27.54. Ascentage Pharma Group International shares last traded at $27.54, with a volume of 1,685 shares traded.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AAPG. BTIG Research initiated coverage on shares of Ascentage Pharma Group International in a report on Monday, November 10th. They set a “buy” rating and a $50.00 price target on the stock. Rodman & Renshaw assumed coverage on Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price for the company. Oppenheimer assumed coverage on Ascentage Pharma Group International in a research report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target on the stock. Truist Financial set a $51.00 price target on Ascentage Pharma Group International in a research note on Monday, November 24th. Finally, Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to MarketBeat.com, Ascentage Pharma Group International presently has an average rating of “Buy” and an average target price of $48.40.

Ascentage Pharma Group International Price Performance

The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. The firm’s 50-day moving average price is $26.91 and its 200 day moving average price is $33.84.

Institutional Trading of Ascentage Pharma Group International

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AAPG. Tema Etfs LLC bought a new position in Ascentage Pharma Group International in the second quarter worth approximately $610,000. XY Capital Ltd increased its stake in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares in the last quarter. UBS Group AG raised its holdings in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International in the second quarter valued at $391,000. Finally, Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International in the third quarter valued at $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.